Cancer Epidemiology, Biomarkers & Prevention i
Instructions for Authors
Scope Introduction, Materials and Methods, Results, Discussion, Ac- knowledgments, References; (‘ancer Epidemio1og’ ’. Biomarkers & Prevention publishes original research on cancer causation and prevention in humans. The following 4. Footnotes, on a page separate from the text. Designate footnotes topics are of special interest: descriptive, analytical, biochemical and consecutively with superscript Arabic numerals; molecular epidemiology; the use of biomarkers to study the neoplastic 5. Tables, on pages separate from the text, with descriptive titles and preneoplastic processes in humans; chemoprevention and other and/or legends; types of prevention trials; and the role of behavioral factors in cancer 6. Figure legends, on pages separate from the text. Define all sym- etiology and prevention. bols and include staining for halftones, where applicable. Particular attention will be given to the identification of factors associated with various aspects of the carcinogenic process, including genetic susceptibility, host factors, infectious agents, chemical and References physical carcinogens, environmental contaminants, dietary components and behavioral factors such as tobacco use and sun exposure. Include only those articles that have been published or are in press. Besides welcomin manuscripts that address individual subjects in Unpublished data or personal communications must be cited as foot- any of the three disciplines, the Editors encourage the submission of notes to the text. Personal communications should be substantiated by manuscripts with an interdisciplinary approach. a letter of permission. Number references in the order of their first mention in the text. Cite only the number assigned to the reference. References must be double- Contents spaced. . Original research articles #{149}Short communications Sample references: #{149}Invited editorials #{149}Letters to the editor 1. Fontham, E. T. H., Correa, P., Wu-Williams, A., Reynolds, P., #{149}Selected review articles #{149}Meeting reports Greenberg, R. S., Buffler, P. A., Chen, V. W., Boyd, P., Alterman, #{149}AACR and ASPO news T., Austin, D. F., Liff, J., and Greenberg, S. D. Lung cancer in nonsmoking women: A multicenter case-control study. Cancer Epidemiol., Biomarkers & Prey., 1: 35-43, 1991. Editorial Policy 2. Reznikoff, C. A., Swaminathan, S., and Verma, A. K. Cultured normal When a manuscript is received for consideration, the Editors assume human uroepithelial cells: a new system for in vitro carcinogenesis studies. and L. Sikeley (cdx.), that no similar paper has been or will be submitted for publication In: M. Webber In Vitro Models for Cancer Research, pp. 63-101 . Boca Raton, FL: CRC Press, 1986. elsewhere. Further, it is understood that all authors listed on a manu- script have agreed to its submission. Upon acceptance, authors must transfer copyright to the American Association for Cancer Research, Inc., the publisher and copyright owner of the journal, prior to publi- Illustrations cation. Once an article is accepted for publication in Cancer Epidemi- Provide four original sets of illustrations (whether line-cut drawings or ology, Biomarkers & Prevention, the information therein is embargoed halftones). Label each figure in pencil on the reverse side with the first from reporting by the media until the mail date of the issue in which the author’s name, figure number, and an arrow indicating top of figure. article appears. The Editors endorse the principles embodied in the Letters and numbers on illustrations should not be smaller than 6-point Declaration of Helsinki and expect that all investigations involving or larger than 12-point type. All illustrations will be published at a humans will have been performed in accordance with these principles. width of approximately 3 inches (8 cm) unless the author requests a A copy of the Declaration is available from the World Medical Asso- greater width. Use tissue overlays to indicate important areas of the ciation, 28, Ave. des Alpes, F-0l210, Ferney-Voltaire, France. photographs that must be reproduced with the greatest fidelity. Journal policy requires that authors, reviewers, and Associate Editors Authors are encouraged to submit color figures. The expense of reveal to the Editor-in-Chief any relationships that they believe could reproducing color photographs must be offset partially by the author. In be construed as causing a conflict of interest with regard to the manu- 1996, the cost of color reproduction charged to authors will be $975 per script submitted for review. color figure. Submit color illustrations on flexible backing.
Manuscript Submission Proofs Mail manuscripts directly to Dr. Pelayo Correa, Editor-in-Chief. Page proofs must be returned to the office of the American Association Submit four original sets (not photocopies) of illustrations along with for Cancer Research within 24 hours of receipt. Return proofs by four copies of the manuscript. Illustrations will be returned to the author overnight mail. Proofs not received by the deadline will be published if the paper is not accepted for publication. If a manuscript is closely without the authors corrections. Accepted manuscripts are regarded related to papers that are in press or have been submitted elsewhere, as final copy and should not be altered substantially in proof. Extensive please provide copies of those papers with your submission. FAX alterations could cause publication delays, and authors will be charged transmission and overnight delivery service will be used to expedite for excessive changes in proof. review and publication.
Typesetting Manuscripts from Computer Disks Publication Fees Cancer Epidemiology, Biomarkers & Prevention welcomes disks to A page charge of $35 per printed page will be levied on all manuscripts expedite production of accepted manuscripts. If your article is accepted accepted for publication. It is understood at the time of submission that the for publication, you will receive instructions regarding disk submission author(s) agree to pay this charge in the event of publication. Under and a form which must be completed and returned with your disk to the exceptional circumstances, when no other source of grant or other support AACR Publications Department within 48 hours of notification of exists, the author(s) may apply to Dr. Margaret Foti, Director of Publica- acceptance. It is the author’s responsibility to ensure that the material tions, AACR Publications Department (see end of page for address) at the on the disk matches the final accepted version of the manuscript. time of submission for a waiver of the page charges. All such applications must be countersigned by an appropriate institutional official stating that no funds are available for the payment of page charges. For More information, Contact: Dr. Pelayo Correa, Editor-in-Chief, CEBP, Department of Pathology, Format Louisiana State University Medical Center, 1901 Perdido Street, New Orleans, LA 701 12-1393. Telephones: (504)529-2848; (504)568-6035; Manuscripts must be written succinctly in clear, grammatical FAX: English. Define abbreviations in an inclusive footnote to the text. (504)529-2849. Double-space on 8 1/2 X 1 1-inch paper. Dot-matrix printing is not Or: acceptable. The format is as follows: Publications Department, American Association for Cancer Research, 1. Title page, including title, authors, and affiliations; Public Ledger Building, 150 South Independence Mall West, Suite 816, 2. A running title of fewer than 50 characters; Philadelphia, PA 19106-3483. Telephone: (215)440-9300; FAX: 3. Text, arranged in this order: Abstract (not more than 250 words), (215)440-9355. AMERICAN ASSOCIATION FOR CANCER RESEARCH 88th Annual Meeting
Frederick P. Li, Program Committee Chairperson Clara Derber Bloomfield, Program Committee Co-Chairperson Stephen H. Friend, Program Committee Co-Chairperson
San Diego Convention Center, San Diego, California April 12-16, 1997 Titles of Major Session (Names of confirmed session organizers are in parentheses)
PLENARY SESSION How Robust Are AntisenselThird Strand Techniques for Gene Genetic Predisposition to Cancer (Louise C. Strong) Disruption?
SYMPOSIA “MEET-THE-EXPERT” SUNRISE SESSIONS Genes, Cell Proliferation, and Antineoplastic Drugs (George F. Angiogenesis Vande Woude) Gene Therapy (Jack A. Roth) Diagnostic, Prognostic, and Therapeutic Aspects of Tumor Strategies for Drug Development Suppressor Genes (David Sidransky) Advances in Our Molecular Understanding of Cell Cycle Regulation Lymphoproliferative Disease (A. Thomas Look) Breast Cancer Genes (Barbara L. Weber) FHIT Gene (Kay Huebner) Metastasis, Adhesion, and Angiogenesis: Mechanisms and Cancer Vaccines (David P. Carbone) Therapeutic Strategies (Marilyn M. Cornwell and Elise C. Lung Cancer Kohn) Costimulatory Molecules in Tumor Immunity Novel Clinical Trials Based on Genetics and Molecular New Approaches to Overcoming Multidrug Resistance (Alan Therapeutics (Stephen H. Friend) F. List) Apoptosis and Cancer Chemotherapy (Michael B. Kastan) Advances in Oncologic Imaging (Michael J. Welch) Identification and Management of Genetic-High-Risk Retinoids and Cancer Prevention (Waun Ki Hong) Individuals (Albert de la Chapelle) Mechanisms of Regulation of p53 Function (Guillermina Demystifying the Role of Cytokines in Tumor Lozano) Immunobiology: Status and Future Utility (Michael A. Cell Cycle Control of Genetic Stability (Geoffrey Wahl) Caligiuri) Farnesyl Transferase Inhibitors (Allen I. Oliff) Telomerase and Clinical Applications (Titia de Lange) B ioinformatics/Genomics Acute Myelocytic Leukemia (Clara Derber Bloomfield) DNA Methylation in Cancer (Stephen B. Baylin) Prostate Cancer (Donald S. Coffey) Chemoprevention in Transgenic Animals (James M. Phang) Colon Cancer (Margaret A. Tempero) Advances in Stem Cell Transplantation Psychosocial Signaling Pathways for Novel Therapeutics (Anthony J. Issues in Cancer Pawson) Advances in the Management of AIDS-related Malignancies Animal Models for Functional Analysis of Tumor Suppressor (Ellen 0. Feigal) Genes (Terry A. Van Dyke) Recent Developments in Our Understanding of Minimal New Techniques for Molecular Diagnostics (Eric S. Lander) Residual Disease (John G. Gribben) Mechanisms of Cellular Senescence (J. Carl Barrett) Ovarian Cancer Update (Robert C. Bast, Jr.) Damage Response Pathways (Philip C. Hanawalt) The Biological Basis of the New International Classification of Gene Interactions with the EnvironmentiCarcinogenesis (Allan Lymphoma Balmain) Recent Developments in Radiotherapy Epidemiology and Pathogenesis of Secondary Cancers Colon Cancer Genes (Frederick P. Li) Extracellular Connections Barrett’s Esophageal Cancer and Tumor Progression Models CONTROVERSY SESSIONS (Brian J. Reid) What Are the Appropriate Therapeutic Uses of Hematopoietic H. Pylon Growth Factors? (Peter J. Quesenberry) Transcriptional Models and Drug Discovery Estrogen Replacement Therapy: Beneficial or Harmful? What is the Value of Mammography in Young and Genetically METHODS WORKSHOPS AND EDUCATIONAL SESSIONS Susceptible Women? To be announced Is the Time Right for Cancer Chemoprevention? (Edward Abstract Deadline: November 12, 1996 Bresnick) Gene Patents: Help or Hindrance to Conquering Cancer? Further Information: AACR Office #{149}Public Ledger Building #{149}Suite What is the Role of Prophylactic Surgery in Breast and 816 #{149}150 S. Independence Mall West #{149}Philadelphia, PA 19106- Ovarian Cancer? (Samuel A. Wells, Jr.) 3483 #{149}TELEPHONE: (215) 440-9300 #{149}FAX: (215) 440-9313 What Are the Appropriate Guidelines for the Use of Archived Email: [email protected] #{149}For up-to-date information visit the AACR Human Tissue? Website at http:llwww.aacr.org $ AS 0 AMERICAN ASSOCIATION FOR CANCER RESEARCH GUIDELINES FOR APPLICATION FOR ACTIVE AND CORRESPONDING MEMBERSHIP \ \ ___
kCER 1
BENEFITS OF MEMBERSHIP Committee which receives applications for corresponding membership. The American Association for Cancer Research (AACR), a scientific Candidates will be notified according to the following schedule: society of over 1 1 ,000 laboratory and clinical cancer researchers, was Receipt of Application founded in 1907 to facilitate communication and dissemination of knowl- in AACR Office ______Notification of Candidate edge among scientists and others dedicated to the cancer problem; to January 1 March foster research in cancer and related biomedical sciences; to encourage the May 1 July presentation and discussion of new and important observations in the September 1 November field; to foster public education, science education, and training; and to A complete application consists of the following material: advance the understanding of cancer etiology, prevention, diagnosis, and 1. 6 copies of the form on the opposite side of this page, with all requested treatment throughout the world. information provided. Members of the AACR enjoy the following benefits: 2. 5 copies of the candidate’s most current curriculum vitae and bibliog- 1. the privilege of sponsoring a proffered paper (abstract) for consider- raphy. ation for presentation at the AACR annual meeting; 3. 5 copies of a letter of recommendation from a nominator who is an 2. an advance copy of the Program and Proceedings of the American active, corresponding, emeritus, or honorary member of the AACR (at Associationfor Cancer Research that contains over 4,000 abstracts of least one copy must be a signed, original letter). This letter should proffered papers presented at the annual meeting; describe the candidate’s achievements in laboratory research, clinical 3. reduced registration rates at annual meetings; investigations, or epidemiological research, and it should affirm that 4. priority notice of small, focussed meetings in the AACR’s exciting this research adheres to accepted ethical scientific standards. -OR- The series of Special Conferences in Cancer Research; nominator may supply the responses requested at the bottom of the 5. substantially reduced registration rates for Special Conferences; application form in the section entitled “STATEMENT OF SUP-
6. opportunities for participation in AACR meetings in North America PORT “ (at least one copy of the form must be the signed original). and abroad with other scientific societies around the world; 4. 5 copies of a letter of recommendation as described in Item 3 above 7. receipt of AACR Newsletters and other important announcements; from a seconder who is an active, corresponding, emeritus, or honorary 8. early notification of and reduced rates for participation in the AACR member of the AACR (at least one copy must be a signed, original Employment Register; letter). -OR- The seconder may supply the responses requested at the 9. an up-to-date Membership Directory of over I 1,000 member re- bottom of the application form in the section entitled “STATEMENT OF searchers in the cancer field; SUPPORT” (at least one copy of the form must be the signed original). 10. the professional benefits of the AACR’s public education activities 5. 5 reprints of each of two publications on which the candidate appears as concerning funding for cancer research and press coverage of the author. As noted above, evidence of patents developed by the candidate latest research findings; may be submitted in lieu of one or both of the publications. If submitting I 1 . the opportunity to participate in three Summer Workshops that foster patents, supply patent number and year awarded. knowledge in the cancer field for young investigators; All material should be collated into five complete sets with the original 1 2. the facilitation of informal scientific exchange with leading research- application form as a covering document and sent to the address given ers in the cancer field; and below. Questions regarding procedures for membership application may 13. many more ongoing benefits. also be directed to the following address: American Association for Cancer Research QUALIFICATIONS FOR MEMBERSHIP Public Ledger Building, Suite 816 Active membership in the AACR is open to investigators who live in 150 5. Independence Mall West the Americas. Individuals who have conducted two years of research Philadelphia, PA 19106-3483 resulting in peer-reviewed publications relevant to cancer, or who have Phone: 215/440-9300 made substantial contributions to cancer research in an administrative or FAX: 215/440-9313 educational capacity, are eligible. If a candidate has conducted research in E-mail: [email protected] an area of biomedical science related to cancer, he or she will qualify for membership. Evidence of patents relevant to cancer research may be RESPONSIBILITIES OF MEMBERSHIP submitted as qualifications for membership in lieu of peer-reviewed Candidates should be aware of the following responsibilities of mem- publications. bership in the AACR. Active members must pay annual dues. In 1996 Corresponding membership is open to persons who are not residents annual dues for active members are $ 1 60, $95 of which is designated for of the Americas. The qualifications for corresponding membership are the AACR journal subscriptions. Newly elected members of the AACR who same as those indicated above for active membership. Visiting scientists have already purchased subscriptions to Cancer Research, Clinical Can- from outside the Americas who intend to return to their countries of origin cer Research, Cell Growth & Differentiation, or Cancer Epidemiology, by the anticipated time of election should apply for corresponding mem- Biomarkers & Prevention at the higher, nonmember rates will receive bership. All other visiting scientists should apply for active membership reimbursement of the unused portion of those subscriptions once their first and transfer to corresponding status upon leaving the Americas. year’s membership dues are paid in full. Graduate and medical students, postdoctoral fellows, and physicians in Corresponding members are required to pay dues ($80 in 1996) and training who do not yet meet the above qualifications for active or may, if they wish, subscribe to Cancer Research, Clinical Cancer Re- corresponding membership should apply for associate membership. search, Cell Growth & Differentiation, or Cancer Epidemiology, Biomar- Forms for associate membership are available from the AACR Office. kers & Prevention at reduced member rates. Applicants elected in March will be responsible for payment of that PROCEDURES FOR APPLICATION year’s dues; applicants elected in July and November will pay dues for the There are three deadlines for the receipt of a membership application: following year. Applicants elected in March and July will be eligible to January 1, May I, and September 1 of each year. The Membership sponsor an abstract for the next annual meeting. Every effort will be made Committee will review all complete applications for active membership to afford the same opportunity to applicants elected in November. that have been received by these deadlines and will submit recommenda- tions on each candidate to the Board of Directors which formally elects all Margaret Foti, Ph.D. members. The same procedure is followed by the Special Memberships Executive Director AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC. Public Ledger Building - Suite 816 . 150 5. Independence Mall West ‘ Philadelphia, PA 19106-3483 P APPLICATION FOR ACTIVE OR CORRESPONDING MEMBERSHIP
NAME OF CANDIDATE: DATE OF BIRTH:______LAST FIRST MI. PRESENT POSITIONRITLE:.... INSTITUTIONAL AFFILIATION:. INSTITUTIONAL ADDRESS: .
(City) (State/Province) (Country) (Postal Code)
TELEPHONE NUMBER:______FAX NUMBER:______E-MAIL NUMBER (CARRIER):
PRIMARY FIELD OF RESEARCH (Please check only one): Biochemistry and Biophysics Biostatistics Carcinogenesis Biology and Genetics Investigations Endocrinology Epidemiology Immunology Biology and Genetics Pharmacology and Experimental Therapeutics (Please specify)
ACADEMIC DEGREES (Including where and when granted)
EXPERIENCE SINCE HIGHEST DEGREE WAS GRANTED (Please list m ost recent first)
PUBLICATIONS (Reprints of two peer-reviewed articles on which the candidate appears as an author must accompany this application. For these two articles list the authors, title, journal, volume, inclusive pages, and year. Do not submit abstracts. If submitting patents, supply patent number and year awarded.)
CANDIDATE CANDIDATE NOMINATED BY*: SECONDED BY*: (Please print) (Please print)
CANDIDATE IS APPLYING FOR (Check one): E ACTIVE Eli CORRESPONDING MEMBERSHIP
STATEMENT OF SUPPORT Instead of submitting letters of recommendation, either the nominator or the seconder or both may complete the following section:
How long has the candidate worked in the field of cancer re- How long has the candidate worked in the field of cancer re- search? years search? years Will the candidate make a long-term contribution to cancer re- Will the candidate make a long-term contribution to cancer re- search? Yes No search? Yes No Does the candidate’s research adhere to accepted ethical stan- Does the candidate’s research adhere to accepted ethical stan- dards? ...Yes No dards? .Yes ..No I therefore recommend this candidate for membership in the American I therefore recommend this candidate for membership in the American Association for Cancer Research. Association for Cancer Research.
Signature of nominator* Date Signature of seconder* Date
See Guidelines for Application on the reverse side of this form for further instructions.
*Both nominator and seconder must be active, corresponding, emeritus, or honorary members of the AACR.
(This form may be reproduced.) I 996 AMERICAN ASSOCIATION FOR CANCER RESEARCH
GUIDELINES FOR APPLICATION FOR ASSOCIATE MEMBERSHIP
QUALIFICATIONS FOR MEMBERSHIP one of these copies must carry the original signatures of both the candidate
Associate membership is open to graduate students, medical students, and the nominator. The application form may be submitted to the Asso- postdoctoral fellows, and physicians in training who are following a ciation Office at any time. course of study or who are working in a research program relevant to After review of applications for associate membership, the Executive cancer. Scientists in training who already have a substantial record of Director will notify candidates of their election or deferral within one publications may wish to apply for active or corresponding membership month of the receipt of the application form. A check for one year’s dues which confers full benefits of membership. payment must accompany the application. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries. This fee will be refunded to any candidate deemed to be BENEFITS OF MEMBERSHIP ineligible for associate membership. Checks should be in U.S. currency, The American Association for Cancer Research (AACR), a scientific made payable to AACR, Inc., and drawn on a U.S. bank. Send the three copies of the application form and the $35 or $45 dues payment to: society consisting of laboratory and clinical cancer researchers, was founded in 1907 to facilitate communication and dissemination of knowl- edge among scientists and others dedicated to the cancer problem; to American Association for Cancer Research foster research in cancer and related biomedical sciences; to encourage Public Ledger Building, Suite 816 presentation and discussion of new and important observations in the 150 S. Independence Mall West field; to foster public education, science education, and training; and to Philadelphia, PA 19106-3483 advance the understanding of cancer etiology, prevention, diagnosis, and Phone: 215/440-9300 treatment throughout the world. Associate members of the AACR enjoy FAX: 215/440-9313 the following benefits: E-mail: [email protected]
1 . the privilege of sponsoring a proffered paper (abstract) for consider- ation for presentation at the AACR annual meeting provided that (a) the associate member is the presenter of the paper and (b) an active, RESPONSIBILITIES OF MEMBERSHIP corresponding, emeritus, or honorary member in good standing of the Associate members must pay annual dues in an amount to be deter- AACR also signs the abstract of the paper in support of the work. (In mined by the AACR Board of Directors. Dues for 1995 and 1996 have this instance, the member who cosigns the abstract does not lose his been set at $35 per year for residents of the Americas and $45 for residents or her own sponsorship privilege.); of other countries. If an application is submitted by August 3 1, the 2. an advance copy of the scientific Program and (if one has been accompanying dues payment will be credited to the current year. Candi- purchased by the associate member) the Proceedings ofthe American dates submitting applications between September 1 and December 3 1 may Association for Cancer Research that contains over 4,000 abstracts of indicate whether they wish their dues payments credited to the current or proffered papers presented at the annual meeting; forthcoming year. Candidates should be aware, however, that associate 3. the privilege of registering for the annual meeting at the low associate members may sponsor an abstract for the annual meeting only if their dues member rate; for the current year are paid. For example, an associate member submit- 4. preferred access to the AACR Employment Register; ting an abstract in November 1995 for the forthcoming annual meeting 5. optional subscriptions to the Association’s high-quality journals Can- must have paid dues for 1995. Any newly elected associate members of cer Research, Clinical Cancer Research, Cell Growth & Differenti- the AACR who have already purchased subscriptions to Cancer Research, ation, and Cancer Epidemiology, Biomarkers & Prevention at reduced Clinical Cancer Research, Cell Growl/i & Differentiation, or Cancer member rates; Epidemiology, Biomarkers & Prevention at the higher, nonmember rate 6. priority notification of events in the AACR’s series of special con- will receive a refund for the unused portion of that subscription upon ferences on timely subjects in the field; receipt of their payment for a member’s subscription. 7. substantially reduced registration rates at special conferences; Each Fall the AACR will send to current associate members an invoice 8. the receipt of AACR newsletters, meeting announcements, and an for dues for the forthcoming year. Payment of this invoice must be up-to-date Membership Directory; accompanied by a statement signed by the associate member’s current 9. the opportunity to participate in three Summer Workshops that foster registrar, dean, or department head, verifying the member’s current aca- knowledge in the cancer field for young investigators; and demic status. The Association’s By-Laws state that dues are payable for 10. the facilitation of informal scientific exchange with leading research- each year in advance by January 1 of the year to which they should be ers in the cancer field. applied. An individual may be an associate member for a maximum of five years. Each year in which an individual pays dues will count as one full year of associate membership. Thus, an associate member who pays PROCEDURES FOR APPLICATION dues for 1995 may retain associate membership until December 31, 1999. Persons wishing to apply for associate membership must use the The Board of Directors may terminate the membership of an associate official application form on the reverse side of these instructions. Each member whose dues are in arrears for two years. candidate for associate membership must be nominated by an active, corresponding, emeritus, or honorary member in good standing of the Margaret Foti, Ph.D. AACR. Three completed copies of the form should be submitted; at least Executive Director AMERICAN ASSOCIATION FOR CANCER RESEARCH, INC.
Public Ledger Building . Suite 816 150 S. Independence Mall West Philadelphia, PA 19106-3483
APPLICATION FOR ASSOCIATE MEMBERSHIP I
NAME OF CANDIDATE:______DATE OF BIRTH:______LAST FIRST MI. INSTITUTIONAL AFFILIATION:______INSTITUTIONAL ADDRESS:
(City) (State/Province) (Country) (Postal Code)
TELEPHONE NUMBER:______FAX NUMBER:______
PRESENT ACADEMIC STATUS/TITLE (Please check only one): E-MAIL NUMBER (CARRIER): ______Graduate Student ______Medical Student Physician in Training Postdoctoral Fellow
PRIMARY FIELD OF RESEARCH (Please check only one): Biochemistry and Biophysics Biostatistics Carcinogenesis ______Cellular Biology and Genetics ______Clinical Investigations Endocrinology Epidemiology Immunology Molecular Biology and Genetics ______Preclinical Pharmacology and ______Virology Other:______Experimental Therapeutics (Please specify)
ACADEMIC DEGREES (Please indicate degree(s) acquired to date along with the name of the academic institution and date of receipt. Provide information on degree currently being sought and the anticipated date of completion of this degree program.)
RELEVANT RESEARCH EXPERIENCE NOT RELATED TO COURSE WORK (Please list most recent first.)
PUBLICATIONS (List the authors, title, journal, volume, inclusive pages, and year of any article in a peer-reviewed journal on which the candidate appears as an author. Do not list abstracts. Continue on a separate sheet, if necessary.)
CANDIDATE NOMINATED BY*:______(Please print) SIGNATURES I hereby apply for associate membership in the American Association for Cancer Research. I have read the instructions on the reverse side of this form, and I understand the privileges and responsibilities of this class of membership. I certify that the statements on this application are true.
Signature of Candidate:______Date:______
I recommend this candidate for associate membership in the American Association for Cancer Research. To the best of my knowledge, the candidate is qualified for this class of membership, and the statements on this application are true.
Signature of Nominator*:______
Submit three copies of this form. At least one copy must contain the original signatures of the candidate and the nominator. Enclose a check in U.S. funds, made payable to AACR, Inc., and drawn on a U.S. bank for one year’s dues. Dues are currently $35 for associate members residing in the Americas and $45 for residents of other countries.
Check one of the following boxes only if this form is being submitted between September 1 and December 31: The enclosed dues payment should be applied to the current forthcoming calendar year. (NOTE: If dues are applied to the forthcoming year, membership will take effect on January 1, but the candidate will not be eligible to sponsor an abstract for presentation at the annual meeting in March on April of that year.) See Guidelines for Application on the reverse side of this form for further instructions.
*Nominator must be active, corresponding. emeritus, or honorary member of the AACR.
(This form may be reproduced.) 1996 Guidelines for Submitting Disks to American Association for Cancer Research Publications
The word processing packages that we prefer are as follows:
MacWrite WordPerfect (DOS, Windows, Microsoft Word (DOS, Windows, and Macintosh) and Macintosh) XyWrite (DOS and Windows)
Also acceptable:
Ability Mass 1 1 SoloWriter AmiPro MS Windows Write Sprint AM S-T X MS Works Stx Appleworks MS Works WP Mac SunWrite ArborTEX Multimate Symphony ArborText Multimate Advantage TEX ClarisWorks WP Nibia T X78 CPT 8000 Nisus (to ASCII file) Text EXecutive CTOS Notewriter Textures Diablo Obun Total Word DisplayWrite OfficeWriter Troff Duet PC Write p T X Einstein PFS First Choice Volkswriter Enable Professional Write VuWriter EXP Q&AWrite Wang 015 Final Word Quark XPress Wang WPS FullWrite RagTime MS Works Wang Writer GemWord Plus (to ASCII file) Window Works IBM Writing Assistant Rich Text Format Windows Write Interleaf RSG (to ASCII file) WiziWord LATEX Signature Wordstar Latex SLITEX Wordstar 2000 Leading Edge SmartWhere WriteNow Lotus Manuscript SmartWrite II Xerox Lotus Write
Software packages that we are unable to translate:
FrameMaker Ready, Set, Go PageMaker Scientific Writer
Disks produced on IBM or IBM-compatible computers are preferred, but those produced on some Apple or Wang computers can also be converted. Because of the file structures and internal coding, we cannot accept disks created on desktop publishing systems or those created on proprietary typesetting systems. We also cannot guarantee that all special characters can be translated. Tabular and mathematical material, such as equations, will not be captured from the disk but will be rekeyed.
To expedite work and for your own security, we do require that you submit a hard copy printout of the disk file. The tables and equations will be keyed from this hard copy. We also need to know the name of the file to be converted, the type of hardware (e.g., IBM PC) on which the files were created, the operating system (e.g., DOS 3.3), and the version of the software (e.g., WordPerfect 5.1) used to create the file.
PLEASE FILL OUT ALL INFORMATION ON REVERSE SIDE AND SUBMIT THIS FORM WITH YOUR DISK. DISKS WILL NOT BE PROCESSED WITHOUT THIS INFORMATION. P
DISK SUBMISSION FORM
AACR journals are now using personal computers to copyedit manuscripts accepted for publication. When submitting a revised manuscript, authors are encouraged to submit an electronic disk of the paper along with the required four hard copy printouts. Disks will ultimately be returned to the authors.
I See reverse for the word processing packages that can be accepted.
File preparation
Please be sure that the file you send is the most recent version of the manuscript and that it matches the most recently submitted printed copy. The file should contain all the parts of the manuscript in one file. Mathe- matical and tabular material, however, will be processed in the traditional manner and may be excluded from the disk file.
Note: AACR does not assume responsibility for errors in conversion of customized software, newly released software, or special characters.
Please label the outside of the disk with the journal name, the first author’s name, a partial title of the manuscript, and the name of the computer file used to access the manuscript on disk. To process your disk efficiently, we need the following information. Please be sure to provide ALL the information.
Name used to access paper on disk: ______Name of computer used (e.g., IBM/PS2): Operating system and version (e.g., DOS 3.3): Word processing program and version (e.g., WordPerfect 5.0): [See reverse for acceptable programs.]
Manuscript number: ______First author: ______Corresponding author (if different from first author): Telephone/FAX numbers: ______
This form (both sides) may be reproduced. r ____ i AUDIO CASSETTE ORDER FORM r ____ L#{231}i Q h 87Th ANNUAL MEETING #{149}American Association for Cancer Research iLc 1i LJ_! . -7 J Programs consist of either I tape/SI 1.50, 2 tapes/$23.00, or 3 tapes/$34.50 (pp ( s INDJ ATED BEFORh EACH TaLE) ( J. . . AUDIO CASSETFE DISCOUNTS OCAN 632 (3 cass., $3430) Symposium 5: Genetic, Environmental, and Behavioral Factors in Cancer Risk l-5casseues $11.50 OCAN 633 (1 cass., $1 1.50) First Joseph H. Burchenal AACR Clinical 6-I I cassettes 5% DISCOUNT Research Award Lecture: Prophylactic Intervention for Malignancy: 12-24 cassettes 10% DISCOUNT The Paradigm ofthe Type 2 Multiple Endocrine Neoplasia 25-48 cassettes 15% DISCOUNT Syndromes (SamuelA. Wells,Jr.) 49 + 20% DISCOUNT OCAN 634 (2 cass., $23) Minonty Issues Committee Symposium: Reflections Programs consist of 1, 2, or 3 cassettes. Prices are listed after each program title. from Scientists: Their Pathways to Success DCAN 635 (1 cass., $11.50) Meet the Expert Sunrise Session: Nuclear OCAN 601 (2 cass., $23) Educational Session 1: Human Pharmacogenetics: Oncogenes: Effects on Cell Cycle Regulation and Neoplastic Molecular Mechanisms and Clinical Relevance in Cancer Treatment Transformation (l’eee ,J. Farnham) OCAN 602 (2 cass., $23) Educational Session 5: Combinatorial Library Methods OCAN 637 (1 cass., $1 1.50) Meet the Expert Sunrise Session: Chemoprevention for Basic Research and Drug Discovery of Cancers Associated with Tobacco Use (Stephen S. Hecht) OCAN 603 (2 cass., $23) Educational Session 3: The Cell Cycle OCAN 638 (1 cass., $11.50) Meet the Expert Sunrise Session: Antiestrogens OCAN 604 (2 cass., $23) Educational Session 4: Beyond the Human Genome (V CraigJordan) Project: Technical Aspects of Genomic Characterization and Its OCAN 639 (1 cass., $1 1.50) Meet the Expert Sunrise Session: Specific Application to Cancer Research Immunotherapy of Melanoma (Philip Livingston) OCAN 605 (3 cass., $34.50) Methods Workshop 1: Quantitative Biology and OCAN 640 (1 cass., $1130) Meet the Expert Sunrise Session: Environmental Pharmacodynamics Carcinogens: Their Impact in Cancer 9ohn A. McLachkzn) OCAN 606 (3 cass., $34.50) Methods Workshop 2: Animal Models: DCAN 641 (1 cass., $1 1.50) Meet the Expert Sunrise Session: Multistage Transgenic and Knockout Mice in Cancer Investigation Mammary Carcinogenesis (Daniel Medina) DCAN 607 (2 cass., $23) Educational Session 2: Bench to Bedside: Opportunities DCAN 642 (2 cass., $23) Symposium 6: Steroid Hormones: Breast and and Pitfalls in the Discovery and Development of Cancer Therapies Prostate Cancer DCAN 608 (2 cass., $23) Educational Session 7: The Homo Sapiens as a Model OCAN 643 (3 cass., $34.50) Symposium 7: Matrix Metalloproteinases and System for Molecular Cancer Research Their Inhibitors DCAN 609 (2 cass., $23) Educational Session 6: Transcriptional Regulatory OCAN 645 (2 csss., $23) Symposium 9: Viral Mechanisms of Carcinogenesis Pathways and the Response to Cellular Stress DCAN 646 (3 cass., $34.50) Mirsisymposium Epidemiology and Prevention DCAN 610 (1 cass., $11.50) Meet the Expert Sunrise Session: Mechanisms of 4: Mechanisms of Chemoprevention Dietary Prevention of Cancer (Di.sne F. Bin) OCAN 647 (3 cass., $3430) Minisymposium Immunology/Biological Therapy OCAN 611 (1 cats., $1130) Meet the Expert Sunrise Session: Challenges in Bone 4: Tumor Antigens and Effector Cell Response Marrow Transplantation (Wilkam S. Dalton) OCAN 648 (3 cass., $34.50) Minisymposium Experimental Therapeutics 12: DCAN 612 (1 cass., $1 1.50) Meet the Expert Sunrise Session: Natural Killer Cells Novel Drug Resistance Mechanisms (RonaldB. Henben,nan) OCAN 649 (3 cass., $3430) Minisymposium Radiobiology/Radiation DCAN 613 (I cass., $11.50) Meet the Expert Sunrise Session: Tumor Oncology 2: Radiation, Apoptosis, and the Cell Cycle Pathophysiology: Role in Delivery ofMolecules, Particles, and Cells OCAN 650 (1 cass., $11.50) Presidential Address: The Evolution in Concepts of (Rakesh K. lain) Drug Resistance: Implications for the Evaluation of New Drugs OCAN 614 (I cass., $1 1.50) Meet the Expert Sunrise Session: Estrogens and Breast osephR. Bertino) Cancer(LovdlA.Jones) OCAN 651 (1 cass., $1 1.50) Fifth American Cancer Society Award Lecture: OCAN 615 ( 1 cass., $11.50) Meet the Expert Sunrise Session: Chromosomal Prevention of Cancer: The Role of Chemoprevention for the Deletions and Cancer: Recent Advances in Mapping Techniques General Population and for Individuals at High Risk Due to Genetic (Funr?izI. Olopade) Defects or Other Factors (Lee W. Wattenbeng) DCAN 616 (I cass., $11.50) Meet the Expert Sunrise Session: Apoptosis: OCAN 652 (1 cass., $11.50) Controversy Session 3: Does Regional Regulation and Oncogenesis (StanleyJ. Korsmeyen) Chemotherapy Work? OCAN 617 (3 cass., $34.50) Plenary Session: The Progress and Promiseof Cancer DCAN 653 (3 cass., $3430) Minisymposium Endocrinology and Signal Research: A Celebration of the Twenty-Fifth Anniversary of the Transduction 5: Retinoid Action National Cancer Act OCAN 654 (3 cats., $3430) Minisymposium Molecular Biology/Biochemistry DCAN 618 (2 cass., $23) Minisymposium Clinical Investigations 1: Leukemia and 13: Cellular and Viral Oncogenes Lymphoma DCAN 655 (3 cass., $34.50) Minisymposium Biology 12: Cell Cycle Genes in DCAN 619 (3 cass., $34.50) Minisymposium Carcinogenesis 1: Biomarkers of Cancer Chemical Exposure DCAN 656 (3 cass., $34.50) Minisymposium Clinical Investigations 6: Minimal DCAN 620 (3 cass., $34.50) Minisymposium Experimental Therapeutics 1: DNA Residual Disease and Predictors of Outcome in Solid Tumors Topoisomerase I and Camptothecins OCAN 657 (2 cass., $23) Symposium 10: Cell Responses to DNA Damaging DCAN 621 (3 cass., $3430) Minisymposium Biology 1: Mechanisms of Apoptosis Agents DCAN 622 (1 cass., $1130) Thirty-Sixth Annual G.H.A. Clowes Memorial OCAN 658 (2 cass., $23) Symposium 11: Drug Resistant Genes: Transcriptional Lecture: Control ofProliferation by the Cell Cycle Clock and Translational Mechanisms (RobertA. Weinberg) OCAN 659 (2 cass., $23) Symposium 12: Melanoma as a Clinical Model DCAN 623 (1 cass., $1 1.50) Controversy Session 1: Are Antioxidants Useful in OCAN 660 (2 cass., $23) Symposium 13: Nutrition and Cancer Cancer Prevention? OCAN 661 (1 cass., $1 1.50) Presentation by NC! Director: Richard D. Klausne OCAN 624 (1 cass., $1 130) Controversy Session 2: Have Preclinical Models in OCAN 662 (1 cats., $11.50) AACR Annual Business Meeting Studies of Drug Resistance Provided Accurate Predictions for OCAN 663 (1 cass., $11.50) Meet the Expert Sunrise Session: Lung Cancer: Clinicians? A Primer (Robert L Comis) OCAN 625 (3 cass., $34.50) Minisymposium Clinical Investigations 3: Clinical OCAN 664 (1 cass., $11.50) Meet the Expert Sunrise Session: NMR as a Pharmacology I Prognosticator of Tumor Therapeutic Response 7crry D. Glickson) DCAN 626 (3 cass., $34.50) Minisymposium Experimental Therapeutics 6: DCAN 665 (1 cass., $11.50) Meet the Expert Sunrise Session: Protein Kinase C New Drugs I in Carcinogenesis (Susan jaken) OCAN 627 (3 cass., $34.50) Minisymposium Molecular Biology/Biochemistry 5: OCAN 666 (1 cass., $11.50) Meet the Expert Sunrise Session: Immunologi. Telomerase I cal Features of AIDS Pathogenesis Jay A. Lei y) DCAN 628 (2 cass., $23) Symposium 1: Tumor Suppressor Genes OCAN 667 (1 cass., $11.50) Meet the Expert Sunrise Session: DNA OCAN 629 (2 cass., $23) Symposium 2: Ovarian Cancer: From the Laboratory Topoisomerases and Their Inhibitors (Yves C. Poinmier) to the Clinic OCAN 668 (1 cass., $11.50) Meet the Expert Sunrise Session: Chemokines DCAN 630 (3 cass., $34.50) Symposium 3: Apoptosis: Manipulating and Leukocyte-Specific Chemotactic and Activating Factors Programmed Cell Death in Cancer (Barrettj Rollins) OCAN 631 (2 cats., $23) Symposium 4: Monoclonal Antibodies: Clinical OCAN 669 (1 cass., $11.50) Meet the Expert Sunrise Session: Childhood Effectiveness Leukemias: The Latest in Treatment (Stephen E. Sallan) OCAN 670 (1 cass., $1 1.50) NIH Grants Session: View from Peer Review DCAN 693 (1 cass., $1 1.50) Meet the Expert Sunrise Session: Radiation OCAN 671 (2 cast., $23) Symposium 14: Endogenous DNA Damage: Sensitization (Theodore S. Lawrence) Detection and Biological Significance DCAN 694 (1 cass., $11.50) Meet the Expert Sunrise Session: Drugs That OCAN 672 (2 cats., $23) Symposium 15: Targeting Growth Factor Interact with Microtubules: An Update (Eric K. Rowinsky) Receptors for Therapy OCAN 695 (1 cass., $1 1.50) Meet the Expert Sunrise Session: Tumor Vaccines OCAN 673 (2 cass., $23) Symposium 16: Aberrant Transcription Factors effreySchlom) and Malignancy OCAN 696 (1 cass., $1130) Meet the Expert Sunrise Session: Prodrugs for OCAN 674 (2 cass., $23) Symposium 17: Thymidylate Synthase and Its Cancer Chemotherapy (l’eterD. Senter) Inhibitors DCAN 697 (1 cass., $1130) Meet the Expert Sunrise Session: Culturing Normal DCAN 675 (3 cass., $3430) Minisymposium Epidemiology and Prevention and Transformed Human Epithelial Cells Manha R. Stampfer) 6: Genetic Epidemiology: Genetic Susceptibility and Gene- DCAN 698 (2 cass., $23) Symposium 22: Cell Adhesion Receptors and the Environmental Interaction Cytoskeleton DCAN 676 (3 cats., $34.50) Minisymposium Experimental Therapeutics OCAN 699 (2 cass., $23) Symposium 23: Drug Metabolizing Enzymes in Cancer 23: Resistance to Platinum Drugs Prevention and Therapy OCAN 677 (3 ca.ss., $34.50) Minisymposium Molecular Biology/ DCAN 6100 (2 cass., $23) Symposium 24: The Cell Cyde and Damage Response Biochemistry 17: Tumor Suppressor Genes I Pathways: Potential Targets for Therapy OCAN 678 (3 cass., $34.50) Minisymposium Biology 16: Host Effects on DCAN 6101 (3 cass., $34.50) Minisymposium Clinical Investigations 13: Phase I Tumor Cells: Angiogenesis Trials OCAN 679 (1 cass., $1 130) Twentieth Richard and Hinda Rosenthal Foundation DCAN 6102 (3 cass., $34.50) Minisymposium Carcinogenesis 15: Signal Award Lecture: The Place of Bone Marrow Transplantation in the Transduction in Tumor Progression Management of Patients with Lymphoma 7ames 0. Armitage) DCAN 6103 (3 cass., $34.50) Minisymposium Experimental Therapeutics 35: OCAN 680 (1 cass., $1 1.50) Late-Breaking Research Session Human Gene Therapy: Early Trial Results and Promising New DCAN 681 (3 cats., $3430) Minisymposium Immunology/Biological Leads Therapy 10: Cytokines and Effector Cells DCAN 6104 (3 cass., $34.50) Minisymposium Molecular Biology/ OCAN 682 (3 cass., $3430) Minisymposium Experimental Therapeutics Biochemistry 25: Microsatellite Instability 29: Epidermal Growth Factor Receptor-directed Therapeutics DCAN 6105 (1 cass., $1 130) Fifteenth Bruce F. Cain Memorial Award Lecture: OCAN 683 (3 cass., $34.50) Minisymposium Carcinogenesis 13: Carcinogen- Beyond DNA Crosslinking (Kurt W. Kohn) DNA Adducts: Influence on Transcription and Replication DCAN 6106 (1 cass., $1 I 30) Controversy Session 4: Is p53/RB Important for OCAN 684 (3 cass., $34.50) Minisymposium Biology 20: Invasion and Therapeutic Outcome? Metastasis OCAN 6108 (3 cass., $34.50) Minisymposium Biology 27: Novel Signaling OCAN 685 (3 cass., $34.50) Symposium 18: Cell Signaling Pathways and Cross-talk OCAN 686 (2 cass., $23) Symposium 19: Cancer Chemoprevention in Humans DCAN 6109 (3 cass., $34.50) Minisymposium Clinical Investigations 15: OCAN 687 (2 cass., $23) Symposium 20: Neuroblastoma: Recent Advances Predictors of Response and Prognosis Markers in Solid Tumors in Biology and Treatment DCAN 6110 (2 cast., $23) Minisymposium Endocrinology and Signal DCAN 688 (2 cass., $23) Symposium 21: Telomerase, Cell Senescence, and Transduction 9: Prostate Cancer II Cancer DCAN 6111 (3 cass., $34.50) Minisymposium Experimental Therapeutics 41: DCAN 689 (I cass., $11.50) DeWitt S. Goodman Lecture: Retinoid X Alkylating Agents and Platinum Analogues II Receptors: Master Regulators of Nuclear Hormone Receptor OCAN 6112 (2 cass., $23) Symposium 25: Tumor Angiogenesis Signaling (Davidj MangdsdonJ) OCAN 6113 (2 cass., $23) Symposium 26: Genetic Predisposition to Cancer OCAN 691 (1 cass., $11.50) Meet the Expert Sunrise Session: Interferons in OCAN 6114 (1 cass., $11.50) NC! Training Workshop Cancer(Ernest C Borden) OCAN 692 (1 cass., $1 1.50) Meet the Expert Sunrise Session: Transcription VIDEO CASSETTE DISCOUNT Factors As Therapeutic Targets (R;chardA. Heyman) Buy entire set of video cassettes, and receive a 10% discounL VIDEO CASSEITES DCAN 650V (1 cass., $39.00) Presidential Address: The Evolution in Concepts EACH VIDEO PROGRAM CONSISTS OF ONE VIDEO, $39.00, of Drug Resistance: Implications for the Evaluation of New UNLESS OTHERWISE NOTED Drugs (JosephR. Bertino) OCAN 617V (2 cass., $78.00) Plenary Session: The Progress and Promise of DCAN 651V (1 cass., $39.00) Fifth American Cancer Society Award Lecture: Cancer Research: A Celebration of the Twenty-Fifth Prevention of Cancer. The Role of Chemoprevention for the Anniversary of the National Cancer Act General Population and for Individuals at High Risk Due to OCAN 622V (1 cass., $39.00) Thirty-Sixth Annual G.H.A. Clowes Genetic Defects or Other Factors (Lee W Wattenbe,y) Memorial Lecture: Control of Proliferation by the Cell Cycle DCAN679V (1 cass., $39.00) Twentieth Richard and Hinda Rosenthal Clock (RobertA. Weinberg) Foundation Award Lecture: The Place of Bone Marrow OCAN 633V (1 cass., $39.00) FirstJoseph H. Burchenal AACR Clinical Transplantation in the Management of Patients with Research Award Lecture: Prophylactic Intervention for Lymphoma 9ames 0. A rnsitage) DCAN 6105V (1 cass., $39.00) Fifteenth Bruce F. Cain Memorial Award I Malignancy: The Paradigm ofthe Type 2 Multiple Endocrine Neoplasia Syndromes (SamuelA. Wells,Jr.) ______Lecture: Beyond DNA Crosslinking (Kurt W. Kohn)
#{149}1__PLEASECOMPLETE AND RETURN ENTIRE FORM PLEASE PRINT
SUB-TOTALAtl TAPEORDER ______SEND TO: TEACh EM, 160 EAST ILLINOIS ST., CHICAGO. IL 6O6lI SUB-TOTAL lpEQTAPEORDER S ______PHONE: (312) 467.0424 #{149}FAX: (312) 467-9271 #{149}TOLL-FREE: 1-800-225.3775 E-MAIL: [email protected] (IL RESIDENTS ADD 8.75% SALES TAR) ______AU tQ $4.00 SHIPPING & HANDLING S ______VIDEO ORDERS 0 CHECK ENCLOSED PAYABLE TO TEACH ‘EM Y!.D.EQ $4.OOITAPE inside U.S.; $8.00 (Please check one) 0 visA $25 MINIMUM ON CREDIT CARD ORDERS S outside U.S.; S & H ($24 MAX) ______DVHS 0 vic CARD# ______TOTAL (IN U.S. FUNDS) 5 ______0 PAL ($15 0 AMEX EXPIRATION DATE ______conversion surcharge)
NAME ______TITLE ______
ORGANIZATION
ADDRESS (NO P0 BOXES) ______CITY ______STATE ______ZIP ______
SIGNATURE TELEPHONE (
PLEASE NOTE: Any defeclive tapes will be replaced. bul lapes are nonrefundahie. Cancer Epidemiology Biomarkers & Prevention
Conti,zued
Cross-Sectional versus Prospective Predictors of Screening Mammography 845 Roshall Bastani. Alinette F. Max vcll. and Clarence Bradlord
:( I1urnrrunJcat(on
Toenail Samples as an Indicator of Drinking Water Arsenic Exposure 849 Margaret R. Karagas. J. Steven MorrIs. JtIII L E. Weiss. Vlckie Spate. Connie Baskett, and E. Robert Grcciihcrg
r’ ieet ng Report
New I)evelopments in Cervical Cancer Screening and Prevention 853 Eduardu Fralico. Kari Syrj;iI1CI1. Chris de Wolf. Julietta Patnick. Alex Fcrcnciy. EupheI1 ia McGoogan. Xavier Bosch. Albert Siliger. Nuhia Mu#{241}oz. Andre Meheus. and Joseph Monsonego
,/‘f\/\( R BuHel r Board 857
,.., n r ) . ‘..: fl -.
1 ?iIfl i(.)O ( 1 858
t ) Aufflc’) I Cancer Epidemiology
:::::,‘ 1: : BiomirI ers ,, ( ) ,, ,,Iii I In
I::\ IS Prevention ‘ ‘:::::‘.:, .. (I.IlI :rifni(.IIi(tI
Research Articles
.\denocarcinomas of the EsOphagus and (; istric Cardia: Medical Conditions, i’ohacco, Alcohol, and 761 Soeioecononiic Factors
/.tR)- li.’ilL! 7.li;iii . Robert (‘. Ktirt/. 1 i ii Stin. Ni ;LrIi ii Karpeh. J r. . ( ;UO-PCI Yi.i. Nina ;;Lrg Is. let lci S. leiti. Stc i.. 1K. (icor opniIo . ii (l Su’an I 1;tilap
Smoking aII(l l)rinking in Relation to Oral l’;I)ithelial I)vsplasia 769
I )oti l i’. I:. NlUr’(..’. Ralph \ . Kati. I )a il ( . Pcndr) s. l’lieudore R. I Iol lord. I)avid J . Knitelikol I. I.Ikn l.iscnhcr . l)i;ine lKu.i... ;iis l Sti aii 1. Nl;i\ sc
Hormone Replacement lheraI)y Is . ssoeiated ith l.o er Risk of Adenomatous Pohps of the Large 779 Bo el: ‘lhe \linnesota (‘ancer Prevention Research Unit Case-Control Stud
.11)1111 I ). l ttcr. Rohcrd 1 . l o t ick. ( ;i- ’gtr ..\ . ( i;iiidiI . I .i ;i I )sdick. Patiicia Elnscr. J;iiiics \Vood. l ;LL ii . I ;L ( a lB h’L Ii . ;i id liii ill;i . .\ . 1 . ni I
StinsLllatorv Influence of Soy Protein Isolate on Breast Secretion in Pre- and Postmenopausal 785 “OIfleIl
N clstil;i I .. lk’tiaLi. Stcplicii R;triic . l:i ccii 13. K i ng. Jciokl I .o cn tcin. John \Vicnckc. Niarion N 1. Lee. ‘Iiike. \1;iii ii Kirk. and I .oii (o :tid
Induction of (‘ ‘tochrome P45() 2,\6 Fxpression in Humans by the Carcinogenic Parasite Infection, 795 0listhorchiasis \iverrini
SOI.tII1L! V;Lt5 S;it;iiti . N1;ttti .\. 1.;in . l ti;iis i;it ‘it)i5L \ tiiit. l aihon Sithitha ,’orn. l II1sor11 v1airi;inii. l isilii \1;uri;iis . l ii I Pclkniseis. I Iclissut R:tit’.cli. ;Lnd \Ielis.;i I . 1a vell-l lkins
(;l c ph riIs . Somatic (‘elI \lLItJtiOn Freqtiencies in Finnish Reinforced Plastics % orkers Exposed 801 to SR rene
\vI I I ani I .. Ri hee. S1e1)hefl ( i. ( i;int. l ich;iid C . I .;in lois. Ronald Fl. Jeissen. i\hti \nttila. Piikko liii lii. I’ .;ti j; l ck;tii. ;tiid I l;iisiiti Nnpp;t
StJl)ilit of \itaniins .\, C, and l’, (‘arotenoids, Lipids, and Testosterone in Whole Blood Stored at 81 1 4 (‘ for (i allil 24 Ilours l)efore SeI)aratu)U of Serum and Plasn a
Ii issotli Ke . Stii ( )akes. ( setis I );i cv. John V1t)Ore. I .aurie \1. L lisioisd. tna J . Niel .oone and
I );t id I . llitiinhaisi l’lit .\ssot.’iatioii I)et%%et.’Il l’articil Int (‘haracteristics and Seruni Concentrations of 3-(’aroteIse, 815 Retinol, Retinvl Paln itate, iiid (t-locopherol ainoisg Participants in the Carotene and Retinol l’:fli(’ I( lrial ( (‘..\Rl l I for l5re ention of I .ung ( ‘ancer
( ;;r\ I :. ( odisi;iis . \lark 1 Isoriiqti I sI . Nlark Ke t I Ii. l arhara Nietch. Ci;tinet ,\ndeisoii. (h lhert S. ( )ii enii. IiRI (:\l l I’
(i,s-1ra1I. l.ycopene Isolners, (‘arotenoids, and Retinol in the Human l’rostate 823
Ste K. ( liittiiit. (‘tirt l.incnhi er. Steven J . Sch ’arIi. I)avid (. Bostviek. i\lexa \\. \Villianss. l iII .J.\looie. 1111l lotus \\. l idinail.li.
Reproducihilit StL1(lies and Interlahoratory (‘oncordance for Assays of Serum Hormone Levels: 835 l’;strOIse, Istradiol, lstrone Sulfate, and Progesterone
, 1 uchel I I I . ( ;Li I. lhoiii;i , R . leai . knhert N . I 1oo er. l)onald \ . (liaiidlei, Jenni Icr I .. I)oiialdson,
\lari;iisiie 13. i1 er. I )a id l5ee. \Viiii I red \ . Ricker. Pentti K. .Siiterl. Frank 1.. Staiietyk.
.Jiiiiinie 13. \;iti lst. and l e iis;i ( . ,/iie lei
( ‘olitinued ill? l,zside Back (‘oi’er